|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Nik NN, Vang R, Shih Ie M and Kurman RJ:
Origin and pathogenesis of pelvic (ovarian, tubal, and primary
peritoneal) serous carcinoma. Annu Rev Pathol. 9:27–45. 2014.
View Article : Google Scholar
|
|
4
|
Jiang W, Jimenez G, Wells NJ, Hope TJ,
Wahl GM, Hunter T and Fukunaga R: PRC1: A human mitotic
spindle-associated CDK substrate protein required for cytokinesis.
Mol Cell. 2:877–885. 1998. View Article : Google Scholar
|
|
5
|
Mollinari C, Kleman JP, Jiang W, Schoehn
G, Hunter T and Margolis RL: PRC1 is a microtubule binding and
bundling protein essential to maintain the mitotic spindle midzone.
J Cell Biol. 157:1175–1186. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kurasawa Y, Earnshaw WC, Mochizuki Y,
Dohmae N and Todokoro K: Essential roles of KIF4 and its binding
partner PRC1 in organized central spindle midzone formation. EMBO
J. 23:3237–3248. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chen J, Rajasekaran M, Xia H, Zhang X,
Kong SN, Sekar K, Seshachalam VP, Deivasigamani A, Goh BK, Ooi LL,
et al: The microtubule-associated protein PRC1 promotes early
recurrence of hepatocellular carcinoma in association with the
Wnt/β-catenin signalling pathway. Gut. 65:1522–1534. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhang B, Shi X, Xu G, Kang W, Zhang W,
Zhang S, Cao Y, Qian L, Zhan P, Yan H, et al: Elevated PRC1 in
gastric carcinoma exerts oncogenic function and is targeted by
piperlongumine in a p53-dependent manner. J Cell Mol Med.
21:1329–1341. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhan P, Xi GM, Liu HB, Liu YF, Xu WJ, Zhu
Q, Zhou ZJ, Miao YY, Wang XX, Jin JJ, et al: Protein regulator of
cytokinesis-1 expression: Prognostic value in lung squamous cell
carcinoma patients. J Thorac Dis. 9:2054–2060. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhan P, Zhang B, Xi G, Wu Y, Liu HB, Liu
YF, Xu WJ, Zhu QQ, Cai F, Zhou ZJ, et al: PRC1 contributes to
tumorigenesis of lung adenocarcinoma in association with the
Wnt/β-catenin signaling pathway. Mol Cancer. 16:1082017. View Article : Google Scholar
|
|
11
|
Rustin GJ, Vergote I, Eisenhauer E,
Pujade-Lauraine E, Quinn M, Thigpen T, du Bois A, Kristensen G,
Jakobsen A, Sagae S, et al: Definitions for response and
progression in ovarian cancer clinical trials incorporating RECIST
1.1 and CA 125 agreed by the Gynecological Cancer Intergroup
(GCIG). Int J Gynecol Cancer. 21:419–423. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
13
|
Plon SE, Eccles DM, Easton D, Foulkes WD,
Genuardi M, Greenblatt MS, Hogervorst FB, Hoogerbrugge N, Spurdle
AB and Tavtigian SV: Sequence variant classification and reporting:
Recommendations for improving the interpretation of cancer
susceptibility genetic test results. Hum Mutat. 29:1282–1291. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Vaughan S, Coward JI, Bast RC Jr, Berchuck
A, Berek JS, Brenton JD, Coukos G, Crum CC, Drapkin R,
Etemadmoghadam D, et al: Rethinking ovarian cancer: Recommendations
for improving outcomes. Nat Rev Cancer. 11:719–725. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Shi T, Wang P, Xie C, Yin S, Shi D, Wei C,
Tang W, Jiang R, Cheng X, Wei Q, et al: BRCA1 and BRCA2 mutations
in ovarian cancer patients from China: Ethnic-related mutations in
BRCA1 associated with an increased risk of ovarian cancer. Int J
Cancer. 140:2051–2059. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fujiwara T, Bandi M, Nitta M, Ivanova EV,
Bronson RT and Pellman D: Cytokinesis failure generating
tetraploids promotes tumorigenesis in p53-null cells. Nature.
437:1043–1047. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Steigemann P, Wurzenberger C, Schmitz MH,
Held M, Guizetti J, Maar S and Gerlich DW: Aurora B-mediated
abscission checkpoint protects against tetraploidization. Cell.
136:473–484. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang Y, Jiang C, Li H, Lv F, Li X, Qian
X, Fu L, Xu B and Guo X: Elevated Aurora B expression contributes
to chemo-resistance and poor prognosis in breast cancer. Int J Clin
Exp Pathol. 8:751–757. 2015.
|
|
20
|
Hetland TE, Nymoen DA, Holth A, Brusegard
K, Flørenes VA, Kærn J, Tropé CG and Davidson B: Aurora B
expression in metastatic effusions from advanced-stage ovarian
serous carcinoma is predictive of intrinsic chemotherapy
resistance. Hum Pathol. 44:777–785. 2013. View Article : Google Scholar
|
|
21
|
Beussel S, Hasenburg A, Bogatyreva L,
Hauschke D, Werner M and Lassmann S: Aurora-B protein expression is
linked to initial response to taxane-based first-line chemotherapy
in stage III ovarian carcinoma. J Clin Pathol. 65:29–35. 2012.
View Article : Google Scholar
|
|
22
|
Davidson B, Nymoen DA, Elgaaen BV, Staff
AC, Tropé CG, Kærn J, Reich R and Falkenthal TE: BUB1 mRNA is
significantly co-expressed with AURKA and AURKB mRNA in
advanced-stage ovarian serous carcinoma. Virchows Arch.
464:701–707. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chen YJ, Chen CM, Twu NF, Yen MS, Lai CR,
Wu HH, Wang PH and Yuan CC: Overexpression of Aurora B is
associated with poor prognosis in epithelial ovarian cancer
patients. Virchows Arch. 455:431–440. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Honma K, Nakanishi R, Nakanoko T, Ando K,
Saeki H, Oki E, Iimori M, Kitao H, Kakeji Y and Maehara Y:
Contribution of Aurora-A and -B expression to DNA aneuploidy in
gastric cancers. Surg Today. 44:454–461. 2014. View Article : Google Scholar
|
|
25
|
Tuncel H, Shimamoto F, Kaneko Guangying,
Qi H, Aoki E, Jikihara H, Nakai S, Takata T and Tatsuka M: Nuclear
Aurora B and cytoplasmic Survivin expression is involved in lymph
node metastasis of colorectal cancer. Oncol Lett. 3:1109–1114.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Takeshita M, Koga T, Takayama K, Ijichi K,
Yano T, Maehara Y, Nakanishi Y and Sueishi K: Aurora-B
overexpression is correlated with aneuploidy and poor prognosis in
non-small cell lung cancer. Lung Cancer. 80:85–90. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Fadri-Moskwik M, Weiderhold KN, Deeraksa
A, Chuang C, Pan J, Lin SH and Yu-Lee LY: Aurora B is regulated by
acetylation/deacetylation during mitosis in prostate cancer cells.
FASEB J. 26:4057–4067. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Premkumar DR, Jane EP and Pollack IF:
Cucurbitacin-I inhibits Aurora kinase A, Aurora kinase B and
survivin, induces defects in cell cycle progression and promotes
ABT-737-induced cell death in a caspase-independent manner in
malignant human glioma cells. Cancer Biol Ther. 16:233–243. 2015.
View Article : Google Scholar :
|
|
29
|
Diaz RJ, Golbourn B, Shekarforoush M,
Smith CA and Rutka JT: Aurora kinase B/C inhibition impairs
malignant glioma growth in vivo. J Neurooncol. 108:349–360. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Vita M and Henriksson M: The Myc
oncoprotein as a therapeutic target for human cancer. Semin Cancer
Biol. 16:318–330. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Baker VV, Borst MP, Dixon D, Hatch KD,
Shingleton HM and Miller D: c-myc amplification in ovarian cancer.
Gynecol Oncol. 38:340–342. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Cancer Genome Atlas Research Network:
Integrated genomic analyses of ovarian carcinoma. Nature.
474:609–615. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Prathapam T, Aleshin A, Guan Y, Gray JW
and Martin GS: p27Kip1 mediates addiction of ovarian cancer cells
to MYCC (c-MYC) and their dependence on MYC paralogs. J Biol Chem.
285:32529–32538. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Reyes-Gonzalez JM, Armaiz-Peña GN, Mangala
LS, Valiyeva F, Ivan C, Pradeep S, Echevarría-Vargas IM,
Rivera-Reyes A, Sood AK and Vivas-Mejía PE: Targeting c-MYC in
platinum-resistant ovarian cancer. Mol Cancer Ther. 14:2260–2269.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kalluri R and Weinberg RA: The basics of
epithelial-mesen-chymal transition. J Clin Invest. 119:1420–1428.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhang Y, Zeng S, Ma J, Deng G, Qu Y, Guo C
and Shen H: Nestin overexpression in hepatocellular carcinoma
associates with epithelial-mesenchymal transition and
chemoresistance. J Exp Clin Cancer Res. 35:1112016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wu Q, Wang R, Yang Q, Hou X, Chen S, Hou
Y, Chen C, Yang Y, Miele L, Sarkar FH, et al: Chemoresistance to
gemcitabine in hepatoma cells induces epithelial-mesenchymal
transition and involves activation of PDGF-D pathway. Oncotarget.
4:1999–2009. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ju BL, Chen YB, Zhang WY, Yu CH, Zhu DQ
and Jin J: miR-145 regulates chemoresistance in hepatocellular
carcinoma via epithelial mesenchymal transition. Cell Mol Biol
(Noisy-le-Grand). 61:12–16. 2015.
|
|
39
|
Lee TY, Liu CL, Chang YC, Nieh S, Lin YS,
Jao SW, Chen SF and Liu TY: Increased chemoresistance via Snail-Raf
kinase inhibitor protein signaling in colorectal cancer in response
to a nicotine derivative. Oncotarget. 7:23512–23520.
2016.PubMed/NCBI
|
|
40
|
Li J, Liu H, Yu J and Yu H:
Chemoresistance to doxorubicin induces epithelial-mesenchymal
transition via upregulation of transforming growth factor beta
signaling in HCT116 colon cancer cells. Mol Med Rep. 12:192–198.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Li Y, Huang S, Li Y, Zhang W, He K, Zhao
M, Lin H, Li D, Zhang H, Zheng Z and Huang C: Decreased expression
of LncRNA SLC25A25-AS1 promotes proliferation, chemore-sistance,
and EMT in colorectal cancer cells. Tumour Biol. 37:14205–14215.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Feng S, Zheng Z, Feng L, Yang L, Chen Z,
Lin Y, Gao Y and Chen Y: Proton pump inhibitor pantoprazole
inhibits the proliferation, selfrenewal and chemoresistance of
gastric cancer stem cells via the EMT/β-catenin pathways. Oncol
Rep. 36:3207–3214. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Jiang L, He D, Yang D, Chen Z, Pan Q, Mao
A, Cai Y, Li X, Xing H, Shi M, et al: MiR-489 regulates
chemoresistance in breast cancer via epithelial mesenchymal
transition pathway. FEBS Lett. 588:2009–2015. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Hu SH, Wang CH, Huang ZJ, Liu F, Xu CW, Li
XL and Chen GQ: miR-760 mediates chemoresistance through inhibition
of epithelial mesenchymal transition in breast cancer cells. Eur
Rev Med Pharmacol Sci. 20:5002–5008. 2016.PubMed/NCBI
|
|
45
|
Jin Z, Guan L, Song Y, Xiang GM, Chen SX
and Gao B: MicroRNA-138 regulates chemoresistance in human
non-small cell lung cancer via epithelial mesenchymal transition.
Eur Rev Med Pharmacol Sci. 20:1080–1086. 2016.PubMed/NCBI
|
|
46
|
Westhoff GL, Chen Y and Teng NNH:
Targeting Foxm1 improves cytotoxicity of paclitaxel and cisplatinum
in platinum-resistant ovarian cancer. Int J Gynecol Cancer.
27:887–894. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Tassi RA, Todeschini P, Siegel ER, Calza
S, Cappella P, Ardighieri L, Cadei M, Bugatti M, Romani C, Bandiera
E, et al: FOXM1 expression is significantly associated with
chemotherapy resistance and adverse prognosis in non-serous
epithelial ovarian cancer patients. J Exp Clin Cancer Res.
36:632017. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Wen N, Wang Y, Wen L, Zhao SH, Ai ZH, Wang
Y, Wu B, Lu HX, Yang H, Liu WC and Li Y: Overexpression of FOXM1
predicts poor prognosis and promotes cancer cell proliferation,
migration and invasion in epithelial ovarian cancer. J Transl Med.
12:1342014. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Zhao F, Siu MK, Jiang L, Tam KF, Ngan HY,
Le XF, Wong OG, Wong ES, Gomes AR, Bella L, et al: Overexpression
of forkhead box protein M1 (FOXM1) in ovarian cancer correlates
with poor patient survival and contributes to paclitaxel
resistance. PLoS One. 9:e1134782014. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Chiu WT, Huang YF, Tsai HY, Chen CC, Chang
CH, Huang SC, Hsu KF and Chou CY: FOXM1 confers to
epithelial-mesenchymal transition, stemness and chemoresistance in
epithelial ovarian carcinoma cells. Oncotarget. 6:2349–2365. 2015.
View Article : Google Scholar :
|
|
51
|
Jin C, Liu Z, Li Y, Bu H, Wang Y, Xu Y,
Qiu C, Yan S, Yuan C, Li R, et al: PCNA-associated factor
P15PAF, targeted by FOXM1, predicts poor prognosis in
high-grade serous ovarian cancer patients. Int J Cancer.
143:2973–2984. 2018. View Article : Google Scholar : PubMed/NCBI
|
